AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2740166
Drug: Weekly home
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly home visiting
Trial: 2740166
Drug: Monthly home
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly home visiting
Trial: 8031165
Drug: 5‐FU administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU administration
Trial: 377539
Drug: Intravenous gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gentamicin and clindamycin
Trial: 24784698
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (200 μg, bid)
Trial: 24784698
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone (4 mg, bid)
Trial: 15236888
Drug: Fusafungine plus
RxNorm normalized name: fusafungin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusafungine plus analgesic (acetaminophen)
Trial: 15236888
Drug: Antibiotic (amoxicillin‐clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic (amoxicillin‐clavulanic acid) plus analgesic (acetaminophen)
Trial: 11943263
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy + Tamoxifen
Trial: 11943263
Drug: Control (never-users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (never-users of hormone replacement therapy)
Trial: 8129156
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg and 8 mg (combined analysis)
Trial: 8129156
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg (study 3)
Trial: 2757151
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with adrenaline 1:200,000 (pH 3.9) 2 mg/kg
Trial: 2757151
Drug: Alkalinised bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinised bupivacaine with adrenaline 1:200,000 (pH 6.4) 2 mg/kg
Trial: 769506
Drug: Amantadine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 400 mg daily
Trial: 769506
Drug: Amantadine 200
RxNorm normalized name: amantadine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 200 mg daily
Trial: 769506
Drug: Amantadine 200
RxNorm normalized name: amantadine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 200 mg daily with pemoline 20 mg daily
Trial: 22022584
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH) treatment
Trial: 22022584
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (40 µg) PTH (1-34)
Trial: 9576972
Drug: PTH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH treatment
Trial: 16285323
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (previous treatment)
Trial: 16285323
Drug: Elimination of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elimination of topical corticosteroids and gradual reduction of skin-care products
Trial: 8179563
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 mcg/kg iv)
Trial: 8179563
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg im)
Trial: 3953214
Drug: 2 grams
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams of dicloxacillin as an intravenous infusion at the induction of anaesthesia
Trial: 3953214
Drug: 2 grams
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams of dicloxacillin as an intravenous infusion 3 hours before surgery
Trial: 3953214
Drug: 2 grams
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams of dicloxacillin as an intravenous infusion approximately 6 hours before surgery
Trial: 29888581
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (2 Hz/100 Hz, 4‐8 mA) applied to specific acupuncture points, 3 times a week for 12 weeks
Trial: 28622156
Drug: Isometric handgrip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isometric handgrip training five times weekly (two contractions of 2 min at 30% of maximal power with each arm)
Trial: 28622156
Drug: Sham-handgrip training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-handgrip training five times weekly (two contractions of 2 min at 5% of maximal power with each arm)
Trial: 25088860
Drug: Ultrasound-guided TAP
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided TAP block (30 mL of 0.25% bupivacaine with epinephrine)
Trial: 25088860
Drug: Laparoscopic-guided TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic-guided TAP block (30 mL of 0.25% bupivacaine with epinephrine)
Trial: 16416114
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy regimen (idarubicin, cytarabine, etoposide) (group A)
Trial: 16416114
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy regimen (group A)
Trial: 11094035
Drug: Spironolactone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (12.5 to 50 mg daily)
Trial: 1798003
Drug: lacidipine (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lacidipine (4-6 mg once a day)
Trial: 7039160
Drug: mexiletine (MEX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mexiletine (MEX; 400 mg)
Trial: 7039160
Drug: mexiletine (MEX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mexiletine (MEX; 600 mg)
Trial: 7039160
Drug: mexiletine (MEX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mexiletine (MEX; 800 mg)
Trial: 7039160
Drug: lorcainide (LOR;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorcainide (LOR; 200 mg)
Trial: 7039160
Drug: lorcainide (LOR;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorcainide (LOR; 300 mg)
Trial: 7039160
Drug: lorcainide (LOR;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorcainide (LOR; 400 mg)
Trial: 31855716
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg) administered into the CPB pump prime
Trial: 29247531
Drug: EMS add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMS add-on therapy
Trial: 25288340
Drug: ropivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine + morphine + ketorolac
Trial: 25288340
Drug: ropivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine + morphine + ketorolac + methylprednisolone
Trial: 25288340
Drug: control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (saline solution, epinephrine, and cefazolin)
Trial: 23925619
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy plus naltrexone (100 mg/d)
Trial: 30516797
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy plus placebo
Trial: 23925619
Drug: Supportive counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive counseling plus naltrexone (100 mg/d)
Trial: 23925619
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg/d)
Trial: 16484702
Drug: Cisplatin administration
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administration at dosages above 60 mg/m2
Trial: 16484702
Drug: Cisplatin administration
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administration once every 2 weeks
Trial: 16939913
Drug: Cisplatin administration
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administration
Trial: 8102427
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single oral dose of 20 mg/kg)
Trial: 8102427
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (6 weeks of topical tetracycline plus erythromycin for severe cases)
Trial: 12566359
Drug: Paclitaxel low
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel low dose (1.28 microg/mm2)
Trial: 12566359
Drug: Paclitaxel high
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel high dose (3.10 microg/mm2)
Trial: 8824691
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol (1.6 mg)
Trial: 1457264
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol (4 mg)
Trial: 1552354
Drug: Protein intakes
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intakes of 0.8 and 1.0 g.kg‐1.d‐1
Trial: 1552354
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake of 0.6 g.kg‐1.d‐1
Trial: 27334885
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.25% bupivacaine and methylprednisolone 16 mg per nerve
Trial: 23841532
Drug: Tadalafil 2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 2.5-5 mg
Trial: 18554657
Drug: Tubeless percutaneous
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubeless percutaneous nephrolithotomy (group 2 treatment)
Trial: 10877459
Drug: Zanamivir 10
RxNorm normalized name: Zanamivir 10 mg/mL solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir 10 mg inhaled bd for 5 days
Trial: 8596268
Drug: Haloperidol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (4 mg by mouth)
Trial: 1370264
Drug: r‐metHuG‐CSF (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐metHuG‐CSF (3 to 10 micrograms/kg/day, daily subcutaneous injection for 4 months after 1 month of dose titration)
Trial: 1370264
Drug: Observation for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation for 4 months followed by r‐metHuG‐CSF treatment
Trial: 6476812
Drug: Rimantadine hydrochloride
RxNorm normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimantadine hydrochloride (RH) 100 mg twice a day
Trial: 29389150
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy for CHR for psychosis
Trial: 29389150
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy for CHR for bipolar disorder
Trial: 17530638
Drug: Bosentan (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (125 mg/day)
Trial: 20394250
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 2% lidocaine (40 mg) and 0.5 mL atracurium (5 mg)
Trial: 20394250
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 2% lidocaine (40 mg) and 0.5 ml 0.9% NaCl (Control)
Trial: 17084621
Drug: Sequential chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemo-radiotherapy (Gemcitabine 1250mg/m² days 1, 8; Cisplatin 75mg/m² day 2)
Trial: 17084621
Drug: Concurrent chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo-radiotherapy (daily low-dose Cisplatin 6mg/m² with radiotherapy 66Gy)
Trial: 17084621
Drug: Concurrent chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo-radiotherapy
Trial: 10430432
Drug: Lexipafant 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lexipafant 500 mg/day
Trial: 7490991
Drug: Short problem‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short problem‐based training course in pharmacotherapy using a WHO manual on rational prescribing.
Trial: 7042363
Drug: Indoprofen 600
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indoprofen 600 mg/day
Trial: 7042362
Drug: Indoprofen 1000
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indoprofen 1000 mg/day
Trial: 7042362
Drug: ASA 3600
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA 3600 mg/day
Trial: 1931060
Drug: Midazolam 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.02 mg/kg
Trial: 15906066
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone (400 mcg)
Trial: 15906066
Drug: Intravitreal vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal vancomycin (0.2 mg)
Trial: 11882229
Drug: Ketoprofen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 0.5 mg.kg-1 at induction followed by continuous infusion of 3 mg.kg-1 over 24 h (preketoprofen group)
Trial: 11882229
Drug: Ketoprofen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 0.5 mg.kg-1 after surgery followed by continuous infusion of 3 mg.kg-1 over 24 h (postketoprofen group)
Trial: 9814468
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy with dose titration starting at 0.8 IU/day subcutaneously (0.4 IU/day if hypertensive or glucose tolerance impaired)
Trial: 9814468
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy with dose titration
Trial: 8695002
Drug: Amalgambond adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amalgambond adhesive agent
Trial: 28167237
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (4000IU/d) vitamin D3
Trial: 28167237
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (4000IU/d) vitamin D3 among those with insufficient 25(OH)D (<75nmol/L) at baseline
Trial: 25714615
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg alternate days, 12 weeks)
Trial: 21685641
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality exposure therapy using head-mounted display (HMD)
Trial: 21685641
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality exposure therapy using computer automatic virtual environment (CAVE)
Trial: 15228844
Drug: Cyclosporin-A in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin-A in combination with methotrexate
Trial: 11471481
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care management by pharmacists in the intervention group.
Trial: 9429994
Drug: Flurbiprofen 50
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50 mg (multiple doses)
Trial: 9429994
Drug: Acetaminophen 300
RxNorm normalized name: acetaminophen 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 300 mg plus codeine phosphate 30 mg (control)
Trial: 3479296
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of 300 mg ofloxacin
Trial: 3479296
Drug: Tablet form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet form of 300 mg ofloxacin
Trial: 3479296
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral solution and tablet form of 300 mg ofloxacin
Trial: 24743712
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 300 mg/d vs 600 mg/d
Trial: 20453723
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (standard decompressive laminectomy)
Trial: 18476982
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg q.d. as add-on to metformin therapy or as monotherapy
Trial: 18476982
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg q.d. as monotherapy
Trial: 16669963
Drug: Bisacodyl, 10
RxNorm normalized name: Bisacodyl, 10 mg rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisacodyl, 10 mg once daily
Trial: 3459738
Drug: Oral prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis immediately
Trial: 3459738
Drug: Oral prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis 6 weeks after baseline
Trial: 30956141
Drug: Attention-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-based training (ABT) program, four sessions (4 h/session) over 7 weeks, practice target of 20 min twice-daily
Trial: 29468642
Drug: 8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml ropivacaine
Trial: 29468642
Drug: 8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml isotonic saline
Trial: 22854412
Drug: High-antioxidant diet
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-antioxidant diet (5 servings of vegetables and 2 servings of fruit daily; n = 46)
Trial: 22854412
Drug: Low-antioxidant diet
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-antioxidant diet (≤2 servings of vegetables and 1 serving of fruit daily; n = 91)
Trial: 15919283
Drug: Low-dose anticoagulation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anticoagulation (target INR range 1.8 to 2.8 for aortic valve replacement and 2.5 to 3.5 for mitral or double valve replacement)
Trial: 15919283
Drug: Conventional-dose anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose anticoagulation (target INR range 2.5 to 4.5 for all heart valve prostheses)
Trial: 9818597
Drug: Combined topical-intracameral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical-intracameral anesthesia (1% lidocaine)
Trial: 9818597
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (2% lidocaine hydrochloride) alone
Trial: 24849736
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 26 vitamins and minerals tablet
Trial: 23873823
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) 300 μg every 2 weeks starting on Day 28 after HCT
Trial: 23873823
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) plus intravenous (i.v.) iron 200 mg on Days 28, 42, and 56
Trial: 23873823
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) plus intravenous (i.v.) iron
Trial: 23873823
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) administration
Trial: 23873823
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) iron administration
Trial: 21726411
Drug: Metformin/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/Placebo
Trial: 21726411
Drug: Insulin Aspart/NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Aspart/NPH Insulin with Metformin/Placebo